Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing innovative therapies to treat a variety of diseases, including cancer and autoimmune disorders. The company specializes in applying its proprietary drug delivery technology to enhance the efficacy and safety of existing therapies, as well as creating new treatments from the ground up. Nektar collaborates with other pharmaceutical organizations to advance its research pipeline and aims to address unmet medical needs by delivering transformative medicines that improve patients' lives. Read More
LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) investors concerning the Company’s possible violations of federal securities laws.
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
The Law Offices of Frank R. Cruz announces an investigation of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) on behalf of investors concerning the Company’s possible violations of federal securities laws.
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, inclusive.
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv- 01951, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nektar securities between February 26, 2025 and December 15, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
LOS ANGELES, March 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025. Nektar describes itself as a “biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders.”
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a novel, first-in-class regulatory T cell stimulator for the treatment of, inter alia, alopecia areata.
As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire founder, Dr. Patrick Soon-Shiong, the company has rapidly evolved into a commercial-stage powerhouse in the immunotherapy landscape. ImmunityBio is currently in focus due to [...]
Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.
